1887
Volume 2023, Issue 2
  • ISSN: 1999-7086
  • EISSN: 1999-7094

Abstract

Diabetic ketoacidosis (DKA) is a common metabolic emergency in diabetic patients encountered by emergency departments (EDs). Euglycemic diabetic ketoacidosis (EDKA) is a rare type of DKA characterized by normal to slightly elevated blood glucose levels. Possible causes of EDKA include fasting, pregnancy, and alcohol consumption.

In this report, we are presenting a case of EDKA associated with the use of empagliflozin, an oral antihyperglycemic medication belonging to the sodium-glucose co-transporter 2 inhibitors (SGLT-2). The case is a 43-year-old diabetic male patient, who presented to the ED complaining of nausea, vomiting, and generalized weakness. Upon history taking, it was found that the patient started taking empagliflozin 10 days ago. Accordingly, appropriate diagnostic tests were requested, and the patient was found to have severe DKA despite normal to slightly elevated blood glucose results. A diagnosis of EDKA was confirmed, and the patient was successfully treated and discharged few days later.

Many reports have linked the use of SGLT-2 inhibitors with an increased risk of developing DKA, especially EDKA. Although the management of DKA and EDKA is similar, it is more challenging to diagnose the latter. We have highlighted these challenges and the most common precipitating factors. Additionally, we highlighted the mechanism for developing EDKA and the appropriate diagnostic approach to follow with diabetic patients using SGLT-2 inhibitors.

Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2023.19
2023-07-02
2024-06-24
Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2023/2/jemtac.2023.19.html?itemId=/content/journals/10.5339/jemtac.2023.19&mimeType=html&fmt=ahah

References

  1. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009; 32:(7):1335–43.
    [Google Scholar]
  2. Long B, Willis GC, Lentz S, Koyfman A, Gottlieb M. Diagnosis and management of the critically ill adult patient with hyperglycemic hyperosmolar state. J Emerg Med. 2021; 61:(4):365–75.
    [Google Scholar]
  3. Westerberg DP. Diabetic ketoacidosis: Evaluation and treatment. Am Fam Physician. 2013; 87:(5):337–46.
    [Google Scholar]
  4. Dreschfeld J. The bradshawe lecture on diabetic coma. Br Med J. 1886; 2:(1338):358–63.
    [Google Scholar]
  5. Fayfman M, Pasquel FJ, Umpierrez GE. Management of hyperglycemic crises: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Med Clin North Am. 2017; 101:(3):587–606.
    [Google Scholar]
  6. Ramphul K, Joynauth J. An update on the incidence and burden of diabetic ketoacidosis in the U.S. Diabetes Care. 2020; 43:(12):e196–e197.
    [Google Scholar]
  7. Munro JF, Campbell IW, McCuish AC, Duncan LJ. Euglycemic diabetic ketoacidosis. Br Med J. 1973; 2:(5866):578–80.
    [Google Scholar]
  8. Long B, Lentz S, Koyfman A, Gottlieb M. Euglycemic diabetic ketoacidosis: Etiologies, evaluation, and management. Am J Emerg Med. 2021; 44::157–60.
    [Google Scholar]
  9. Perry RJ, Shulman GI. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks. J Biol Chem. 2020; 295:(42):14379–90.
    [Google Scholar]
  10. Minze MG, Will KJ, Terrell BT, Black RL, Irons BK. Benefits of SGLT2 inhibitors beyond glycemic control - A focus on metabolic, cardiovascular and renal outcomes. Curr Diabetes Rev. 2018; 14:(6):509–17.
    [Google Scholar]
  11. Puckrin R, Saltiel M-P, Reynier P, Azoulay L, Yu OHY, Filion KB. SGLT-2 inhibitors and the risk of infections: A systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018; 55:(5):503–14.
    [Google Scholar]
  12. Peters AL, Henry RR, Thakkar P, Tong C, Alba M. Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care. 2016; 39:(4):532–8.
    [Google Scholar]
  13. Bamgboye AO, Oni IO, Collier A. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: A review. Eur J Clin Pharmacol. 2021; 77:(5):651–7.
    [Google Scholar]
  14. Meyer EJ, Gabb G, Jesudason D. SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: A South Australian clinical case series and Australian spontaneous adverse event notifications. Diabetes Care. 2018; 41:(4):e47–e49.
    [Google Scholar]
  15. Mistry S, Eschler DC. Euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors and a ketogenic diet: A case series and review of literature. AACE Clin Case Rep. 2020; 7:(1):17–9.
    [Google Scholar]
  16. Ata F, Yousaf Z, Khan AA, Razok A, Akram J, Ali EAH, et al. SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. Sci Rep. 2021; 11:(1):10293.
    [Google Scholar]
  17. Tuttle KR, Brosius III FC, Cavender MA, Fioretto P, Fowler KJ, Heerspink HJL, et al. SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: Report of a scientific workshop sponsored by the national kidney foundation. Am J Kidney Dis. 2021; 77:(1):94–109.
    [Google Scholar]
  18. Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016; 374:(11):1094.
    [Google Scholar]
  19. Guthrie R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. Postgrad Med. 2018; 130:(2):149–53.
    [Google Scholar]
  20. Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021; 372::m4573.
    [Google Scholar]
  21. Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes Metab Res Rev. 2017; 33:(8).
    [Google Scholar]
  22. Diaz-Ramos A, Eilbert W, Marquez D. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: A case report and review of the literature. Int J Emerg Med. 2019; 12:(1):27.
    [Google Scholar]
  23. Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015; 21:(5):512–7.
    [Google Scholar]
  24. Donnan K, Segar L. SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. Eur J Pharmacol. 2019; 846::23–9.
    [Google Scholar]
  25. Dizon S, Keely EJ, Malcolm J, Arnaout A. Insights into the recognition and management of SGLT2-inhibitor-associated ketoacidosis: It’s not just euglycemic diabetic ketoacidosis. Can J Diabetes. 2017; 41:(5):499–503.
    [Google Scholar]
/content/journals/10.5339/jemtac.2023.19
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error